The National Health Surveillance Agency (Anvisa) this Monday (24) approved the final registration of Pfizer’s Comirnaty bivalent vaccine against Covid19. 
The immunizer is indicated for the prevention of Covid19 and can be used by people from 5 years of age. The indication is that it is used only as a booster dose, that is, it can only be used in people who have already been vaccinated against the disease, and it must be used at least three months after the last dose taken.
The vaccine has already been used under the Ministry of Health (MS) National Immunization Program (PNI) for emergencies. Prior to final registration, the product was used as a booster dose for the population over 12 years of age with comorbidities and for those over 18 years of age.
Bivalent
According to Anvisa, bivalent vaccines offer better protection against the disease because they contain a mix of strains of the SarsCoV2 virus. The bivalent Comirnaty is made from the original variant, the Wuhan strain, as well as a newer, circulating variant, the Omicron strain.
In the international regulatory scenario, the bivalent Comirnaty is already approved for use by the European Medicines Agency (EMA) and the United States regulator (Food and Drug Administration FDA).
Listen National Radio Agency: